Compare Evergy Inc. Common Stock (EVRG) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Evergy Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Evergy Inc. Common Stock trades at $82.56 (market cap $18.94B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Evergy Inc. Common Stock is the larger of the two by market cap, and Evergy Inc. Common Stock pays a 3.38% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Evergy Inc. Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| EVRG | RGEN | |
|---|---|---|
Market Cap | $18.94B | $11.31B |
Volume | 1,640,293 | 1,216,919 |
Sector | Utilities | Health |
52-Week High | $88.13 | $194.57 |
52-Week Low | $72.31 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $35.41B | $11.20B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Evergy (EVRG) trades at $82.13, up 0.77% today, with a bullish technical signal and strong support near $80. The stock shows solid fundamentals with a P/E of 20.9 and net income margin of 15.19%, supported by recent earnings beats in Q1 and Q2 2026. Positive sentiment is driven by data center demand growth and a $21.6 billion investment plan, as highlighted in recent news.
The outlook for EVRG is positive, with analyst consensus pointing to a $89.83 price target and 38.89% buy ratings. Key opportunities include load growth from data center contracts and projected 6-8% EPS growth through 2030. Risks involve regulatory challenges, high capital expenditures, and potential volatility from interest rate sensitivity.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Evergy Inc. Common Stock
Evergy is a regulated electric utility serving customers in Kansas and Missouri. Its operations include electricity generation, transmission, and distribution through its integrated utility subsidiaries.
Read more on EVRG →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
